Puma Biotechnology Inc. buy ProvisionYield47
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 30.09.24. The prediction end date can be changed by ProvisionYield47 at any time.Puma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
Name | 1w |
---|---|
Puma Biotechnology Inc. | - |
iShares Core DAX® | 1.560% |
iShares Nasdaq 100 | 0.517% |
iShares Nikkei 225® | 1.730% |
iShares S&P 500 | 1.482% |